Psychiatry is currently the most advanced area of application for Medincell’s technology, with UZEDY® already commercialized in the U.S. and olanzapine LAI under regulatory review. In this field, treatment adherence can have a major impact on patient outcomes.
Long-Acting Medicines
Advancing Treatment Adherence. Improving Lives.
Medincell’s Partner Teva Presented New Data on Investigational Olanzapine LAI and UZEDY® at Psych Congress 2026
Medincell’s Partner Teva Presented New Data on Investigational Olanzapine LAI and UZEDY® at Psych Congress 2026
Read MorePublication of the Notice of Meeting and Reminder of the Participation terms in the Combined General Meeting
Publication of the Notice of Meeting and Reminder of the Participation terms in the Combined General Meeting
Read MoreMedincell appoints Edna Venneker, MD, as Chief Medical Officer
Medincell appoints Edna Venneker, MD, as Chief Medical Officer
Read MoreUZEDY®: Record Q2 Net Sales of $77M, Up 43% YoY; Teva Raises 2026 Outlook
UZEDY®: Record Q2 Net Sales of $77M, Up 43% YoY; Teva Raises 2026 Outlook
Read More80
%
Of patients with chronic diseases fail to adhere to their treatment*
Long-acting injectables reduce dosing frequency to help improve adherence, a key driver of real-world effectiveness
What is a Long-Acting Injectable?
Our innovative technology platform is designed to turn selected medicines into long-acting injectable treatments that release the active ingredient over days, weeks, or months after a single injection.
Watch the video to discover how our long-acting injectable treatments work and their potential benefits
Portfolio
Addressing Adherence Challenges in Psychiatry
UZEDY®
Partnership with Teva
Approved by the FDA in 2023
UZEDY® is a long-acting subcutaneous injection of risperidone for the treatment of adults with schizophrenia (1- and 2-month dosing) and bipolar I disorder (1-month dosing).
Olanzapine LAI
mdc-TJK
Partnership with Teva
Under regulatory review in the United States and Europe
A one-monthly subcutaneous injection of olanzapine for the treatment of Schizophrenia in adults, designed to expand long-acting treatment options to additional patient populations.
Pipeline
Advancing a Scalable Long-Acting Injectables Pipeline
Alongside psychiatry, Medincell is building a diversified pipeline of long-acting injectable therapies across multiple therapeutic areas, through in-house developments and strategic partnerships.
Number or programs by stage
Our pipeline combines programs based on approved or clinical-stage medicines, leveraging our evolving technology platform to build a scalable portfolio in collaboration with leading pharmaceutical partners and global health organizations.
Investors
The Shift to Growth Strategy
“The foundations are in place. The strongest catalysts for growth are still ahead of us. And we believe we are only beginning to unlock the full value of our platform and the opportunities it can create for patients, partners and shareholders.”
Christophe DouatChief Executive Officer
Medincell Insights
Learn from our experts
Inside Medincell – Ep 1
Inside Medincell – Ep 2
Inside Medincell – Ep 3
Inside Medincell – Ep 4
Inside Medincell – Ep 5
R&D Day
Careers
Join the team
Unleash your entrepreneurial spirit within a creative and innovative team of international experts dedicated to tackling global health challenges.
150
Top-tier experts, all shareholders, steering our company’s success.
29
Nationalities within our team, fostering a diverse and dynamic work environment.
